Qiagen NV

NYSE:QGEN  
47.64
-0.07 (-0.15%)
Products, Strategic Combinations

Bio-Techne And Qiagen Announce Expansion And Extension Of Exosome Partnership

Published: 09/17/2020 11:06 GMT
Qiagen NV (QGEN) - Bio-techne and Qiagen Announce Expansion and Extension of Exosome Partnership.
Agreement Grants Qiagen a Non-exclusive Development License to Bio-techne's Exosome Technology for Development of Companion in Vitro Diagnostic Products (cdx-ivd) for Existing and Potential Biopharma Partners.
Initial Phase of Co-marketing Agreement Lasts 24 Months, With Potential to Extend Longer Upon Fulfillment of Certain Conditions.
Extended Collaboration and Joint Product Development Agreement Ends in 2028 and Can Be Extended If Mutually Agreed to by Both Companies.